The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 16, 2008

Filed:

Sep. 06, 2005
Applicants:

John M Nuss, Danville, CA (US);

Stephen D Harrison, Albany, CA (US);

David B Ring, Palo Alto, CA (US);

Rustum S Boyce, San Francisco, CA (US);

Kirk Johnson, Moraga, CA (US);

Keith B Pfister, San Ramon, CA (US);

Savithri Ramurthy, Walnut Creek, CA (US);

Lynn Seely, Burlingame, CA (US);

Allan S Wagman, Oakland, CA (US);

Manoj C Desai, Pleasant Hill, CA (US);

Barry H Levine, Lafayette, CA (US);

Inventors:

John M Nuss, Danville, CA (US);

Stephen D Harrison, Albany, CA (US);

David B Ring, Palo Alto, CA (US);

Rustum S Boyce, San Francisco, CA (US);

Kirk Johnson, Moraga, CA (US);

Keith B Pfister, San Ramon, CA (US);

Savithri Ramurthy, Walnut Creek, CA (US);

Lynn Seely, Burlingame, CA (US);

Allan S Wagman, Oakland, CA (US);

Manoj C Desai, Pleasant Hill, CA (US);

Barry H Levine, Lafayette, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/497 (2006.01); C07D 241/36 (2006.01); C07D 471/00 (2006.01); C07D 487/00 (2006.01); C07D 403/00 (2006.01); C07D 401/00 (2006.01); C07D 405/00 (2006.01);
U.S. Cl.
CPC ...
Abstract

New pyridine-based compounds of Formula I, compositions, and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3-mediated disorders in vivo are provided. The methods, compounds, and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.


Find Patent Forward Citations

Loading…